Strategic collaboration agreement with Sandoz to develop digital anti-infectives platform.
Collaboration leverages Ares Genetics’ antibiotic resistance database ARESdb
Short-term focus on repurposing existing antibiotics to treat infections with multi drug resistant pathogens
Ares Genetics GmbH signed a collaboration agreement with Sandoz to leverage Ares Genetics’ database on the genetics of antibiotic resistance, ARESdb, and the ARES Technology Platform for Sandoz’ anti-infective portfolio.
Under the agreement, the companies intend to develop a digital anti-infectives platform combining established microbiology laboratory methods with advanced bioinformatics and artificial intelligence methods to support drug development and life cycle management. The collaboration in the short- to mid-term aims at rapidly and cost-effectively re-purposing existing antibiotics and designing value-added medicines with the objective of expanding indication areas and overcoming antibiotic resistance, in particular in infections with bacteria that already developed resistance against multiple treatment options. Longer-term, the platform is expected to inform the development of novel anti-infectives that are less prone to encounter resistance and thereby preserve antibiotics as an effective treatment option.
The collaboration agreement covers the first phases of the collaboration with Sandoz providing certain R&D funding to Ares Genetics. Further financial details were not disclosed.